Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Next Previous
Trial Profile

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aceclidine (Primary) ; Aceclidine/brimonidine (Primary)
  • Indications Presbyopia
  • Focus Adverse reactions; Registrational
  • Acronyms CLARITY-3
  • Sponsors LENZ Therapeutics

Most Recent Events

  • 01 Dec 2025 According to a LENZ Therapeutics media release, based on positive data from (CLARITY-1,CLARITY-2 AND CLARITY-3 ) trials, a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for the treatment of presbyopia in adults in South Korea.
  • 02 Apr 2024 According to a LENZ Therapeutics media release, The Company will host a conference call and webcast today, Wednesday, April 3, 2024, at 8:00 a.m. ET to discuss the topline results
  • 02 Apr 2024 Topline Results presented in the LENZ Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top